Gainers
- Codex DNA, Inc. (NASDAQ:DNAY) rose 64.5% to $3.52 in pre-market trading after declining 10% on Tuesday.
- Quotient Limited (NASDAQ:QTNT) rose 57.8% to $0.5896 in pre-market trading. Quotient said it expects to report reagent business generated product sales of $9.8m in the fourth quarter of Fiscal 2022. The company also sees FY22 revenue of $38.5 million.
- U.S. Well Services, Inc. (NASDAQ:USWS) rose 37.7% to $0.9898 in pre-market trading after ProFrac Holding Corp. (NASDAQ:PFHC) announced plans to acquire the company for $1.21 per share in an all-stock deal.
- Precision BioSciences, Inc. (NASDAQ:DTIL) shares rose 33.8% to $1.86 in pre-market trading as the company reported a $50 million offering of common stock and announced in vivo gene editing collaboration with Novartis to develop potentially curative treatment for disorders including sickle cell disease.
- Revlon, Inc. (NYSE:REV) rose 26.9% to $7.69 in pre-market trading on continued volatility following the company's recent bankruptcy filing and approval of a $375 million loan. The stock has also been circulated as a short squeeze candidate.
- Regis Corporation (NYSE:RGS) rose 12.1% to $0.74 in pre-market trading. Regis recently announced a partnership with Zenoti.
- Clovis Oncology, Inc. (NASDAQ:CLVS) shares rose 11% to $1.82 in pre-market trading after jumping 39% on Tuesday. Clovis Oncology, last week, announced a presentation detailing initial Phase 1 data from Phase 1/2 LuMIERE clinical study of FAP-2286 labeled with lutetium-177 (177Lu-FAP-2286).
- La-Z-Boy Incorporated (NYSE:LZB) rose 7.7% to $24.50 in pre-market trading after the company reported upbeat results for its fourth quarter and issued strong sales forecast for the first quarter.
- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA) rose 6.3% to $4.37 in pre-market trading after declining 7% on Tuesday. Comera Life Sciences was recently granted a US patent titled 'Excipient compounds for protein processing.'
